Salidroside-loaded exosome as well as preparation method and application thereof

By treating intrauterine adhesions with exosomes loaded with rhodioloside, the method utilizes ultrasound incubation to load rhodioloside into human umbilical cord mesenchymal stem cell exosomes, overcoming the shortcomings of existing technologies in combining rhodioloside and exosomes. This approach effectively inhibits endometrial inflammation and fibrosis and improves pregnancy rates.

CN118976003AInactive Publication Date: 2024-11-19CHENGDU JINXIN BOYUE BIOTECHNOLOGY CO LTD

Patent Information

Application Number
CN202411050823.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-01
Publication Date
2024-11-19
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

In existing technologies, the combined application of rhodioloside and exosomes in the prevention or treatment of intrauterine adhesions has not fully demonstrated its advantages. Patients with moderate to severe intrauterine adhesions have a high recurrence rate, and existing treatment methods cannot effectively improve the inflammatory microenvironment and fibrosis of the endometrium.

Method used

Rhodioloside was loaded into human umbilical cord mesenchymal stem cell exosomes using an ultrasound incubation method to prepare rhodioloside-loaded exosomes. These exosomes were then injected into the endometrium after hysteroscopic adhesiolysis. The exosomes were used as carriers to deliver rhodioloside to inhibit endometrial inflammation and fibrosis.

Benefits of technology

It significantly inhibits endometrial inflammation and fibrosis, improves pregnancy rate, and is more effective in treating intrauterine adhesions than using rhodioloside or exosomes alone, while reducing the recurrence rate of intrauterine adhesions.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118976003A_ABST
    Figure CN118976003A_ABST
Patent Text Reader

Abstract

The invention belongs to the field of biological medicine, and discloses a salidroside-loaded exosome and a preparation method and application thereof.The salidroside-loaded exosome contains human umbilical cord mesenchymal stem cell exosome and salidroside and can be used for preparing medicine for treating intrauterine adhesion. The method comprises the following steps: firstly, separating human umbilical cord mesenchymal stem cell exosomes, and then carrying salidroside by using the human umbilical cord mesenchymal stem cell exosomes through an ultrasonic incubation method to obtain the salidroside-loaded exosomes. The human umbilical cord mesenchymal stem cell exosome is used as a carrier to carry the salidroside to treat intrauterine adhesion, the salidroside-loaded exosome is adopted to treat a patient after an intrauterine adhesion decomposition operation under a hysteroscope, endometritis and fibrosis of the patient can be inhibited, the pregnancy rate is increased, and the treatment effect is good. And the effect of treating intrauterine adhesion is obviously superior to that of singly adopting salidroside for treatment and is also obviously superior to that of singly adopting exosome for treatment.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of medicine and biomedicine, and more specifically, the present invention relates to exosomes loaded with salidroside, a preparation method of exosomes loaded with salidroside, and application of exosomes loaded with salidroside in the preparation of a drug for treating intrauterine adhesions. Background Art

[0002] Intrauterine adhesions (IUA) refer to adhesions in the uterine cavity or cervical canal caused by damage to the basal layer of the endometrium due to various causes, and the pathological manifestation is endometrial fibrosis. The main causes of intrauterine adhesions include miscarriage, repeated intrauterine operations, myomectomy and infection, and common clinical manifestations include decreased menstrual volume, pelvic inflammatory disease, recurrent miscarriage, infertility and placental abnormalities. Hysteroscopic intrauterine adhesion decomposition and postoperative use of biological barriers to prevent adhesion recurrence or combined oral estrogen drugs to promote endometrial growth are currently common clinical treatments for intrauterine adhesions. However, the recurrence rate of patients with moderate and severe intrauterine adhesions is extremely high after surgery. The repeated cycle of "hysteroscopic observation-hysteroscopy" treatment mode brings huge economic and physical and mental pressure to patients, seriously affecting their quality of life.

[0003] At the same time, hysteroscopic intrauterine adhesion lysis and postoperative use of biological barriers to prevent adhesion recurrence or combined oral estrogen drugs to promote endometrial growth cannot improve the inflammatory microenvironment and fibrosis of the endometrium, resulting in recurrent intrauterine adhesions in many patients.

[0004] Exosomes are double-membrane vesicles with a diameter of 30 to 150 nm that are secreted and released by living cells into the extracellular matrix. They are widely present in various body fluids. Exosomes from different sources, such as mesenchymal stem cell (MSCs) exosomes, menstrual stem cell-derived exosomes, and human pluripotent stem cell exosomes, have been used in biomedicine. Recent studies have found that MSCs exosomes are closely related to fibrosis of various tissues and organs, including endometrial fibrosis. The regulatory mechanism of MSCs exosomes in participating in endometrial fibrosis and promoting the regeneration and repair of damaged endometrium is mainly reflected in inhibiting epithelial mesenchymal transition (EMT), promoting endometrial cell proliferation and angiogenesis, and participating in inflammation and immune regulation. In addition, exosomes can be loaded with different types of drugs as carriers. In terms of preventing or treating intrauterine adhesions, there have been technologies that disclose the use of exosomes loaded with resveratrol to prevent intrauterine adhesions to a certain extent; or directly injecting exosomes derived from menstrual blood cells into the endometrium to inhibit endometrial fibrosis and prevent intrauterine adhesions.

[0005] Salidroside is a biologically active ingredient with extremely high medicinal value. As a natural compound, it has anti-fibrotic effects in various fibrotic diseases (fibrosis of the liver, lung, kidney, myocardium, etc.). In addition, studies have shown that salidroside also has the effect of reducing the inflammatory response of the endometrium, and is therefore widely used in related traditional Chinese medicine compositions for the treatment of intrauterine diseases.

[0006] Although exosomes and salidroside have been used separately in the prevention or treatment of uterine cavity diseases (including uterine cavity adhesions), the combined application of salidroside and exosomes has not yet shown more advantages in this field. CN115645450A discloses the use of rhodiola rosea or salidroside in the preparation of a preparation for protecting and / or regulating cell exosomes, using rhodiola rosea or salidroside to protect and / or regulate exosomes under hypoxic conditions, regulate cell expression, and promote the production of exosomes. Summary of the invention

[0007] In view of the current situation that salidroside and exosomes are underutilized in the prevention or treatment of intrauterine adhesions in the prior art, the present invention proposes an exosome loaded with salidroside, and also provides a preparation method thereof and an application of the exosome in the preparation of a medicament for treating intrauterine adhesions, so that the combination of salidroside and exosomes has a better effect in treating intrauterine adhesions than the use of salidroside and exosomes alone.

[0008] The first aspect of the present invention provides a method for preparing exosomes loaded with salidroside, the preparation method comprising the following steps:

[0009] 1. Isolation of human umbilical cord mesenchymal stem cell exosomes (Exos);

[0010] 2. Using human umbilical cord mesenchymal stem cell exosomes to carry salidroside: Exosomes loaded with salidroside (abbreviated as salidroside-Exos) were prepared by ultrasonic incubation.

[0011] Compared with the prior art, the present invention has at least the following beneficial effects:

[0012] The present invention utilizes human umbilical cord mesenchymal stem cell exosomes (Exos) as carriers to carry salidroside to treat intrauterine adhesions. After hysteroscopic intrauterine adhesion decomposition surgery, the exosomes loaded with salidroside are used to treat patients, which can inhibit the patient's endometrial inflammation and fibrosis, improve the pregnancy rate, and the effect of treating intrauterine adhesions is significantly better than treatment with salidroside alone, and is also significantly better than treatment with exosomes alone.

[0013] Further, in the preparation method of exosomes loaded with salidroside, the process of isolating human umbilical cord mesenchymal stem cell exosomes may include: collecting human umbilical cord mesenchymal stem cell (hUC-MSCs) culture supernatant, and isolating exosomes using ultracentrifugation. Ultracentrifugation is only one of the available methods for isolating human umbilical cord mesenchymal stem cell exosomes in the present invention, which can quickly obtain human umbilical cord mesenchymal stem cell exosomes, and the operation process is simple.

[0014] In more detail, the isolation of human umbilical cord mesenchymal stem cell exosomes can be carried out by the following steps:

[0015] Precool a low-speed centrifuge and a low-speed ultracentrifuge to 4°C, centrifuge the culture supernatant of human umbilical cord mesenchymal stem cells at 300×g and 4°C for 10 min in a low-speed centrifuge to remove cell debris;

[0016] The supernatant after centrifugation was transferred to an ultracentrifuge tube, filled with saline, and centrifuged at 29500×g, 4°C for 20 min in a low-temperature ultracentrifuge to further remove cells and debris;

[0017] The supernatant was filtered through a filter with a pore size of 0.22 μm, and after filtration, the supernatant was transferred to another ultracentrifuge tube and centrifuged in a low-temperature ultracentrifuge at 120,000 × g, 4°C for 90 min;

[0018] The supernatant was discarded, and the liquid on the wall of the ultracentrifuge tube was absorbed with sterile filter paper. The bottom of the ultracentrifuge tube was exosomes (Exos). Physiological saline was added to the exosomes and stored at -80°C for later use.

[0019] The low-temperature low-speed centrifuge generally refers to a centrifuge capable of centrifugation at 4°C with a relative centrifugal force within 15,000×g. The low-temperature low-speed centrifuge used in the present invention can be centrifuged at 300g and 4°C.

[0020] The low-temperature ultracentrifuge generally refers to a centrifuge capable of centrifugation at 4°C with a relative centrifugal force of more than 20,000×g. The low-temperature ultracentrifuge used in the present invention can be centrifuged at 20,000-150,000×g.

[0021] The present invention adopts a low-temperature low-speed centrifuge and a low-temperature ultracentrifuge to perform centrifugation. The low-temperature low-speed centrifuge can quickly remove large cell fragments, thereby laying a foundation for the subsequent separation of human umbilical cord mesenchymal stem cell exosomes. The low-temperature ultracentrifuge can effectively remove cells and small fragments, thereby separating Exos. Under the centrifugal force conditions selected by the present invention, the separation of human umbilical cord mesenchymal stem cell exosomes has the characteristics of high efficiency, and low-temperature centrifugation maintains the activity of human umbilical cord mesenchymal stem cell exosomes.

[0022] Optionally, in the method for preparing exosomes loaded with salidroside, the ultrasonic incubation method is: salidroside (10-100 mg) and exosomes (1×10 10 -1×10 12 , calculated by the number of vesicles) was dissolved in physiological saline, and after sonication in an ice bath, the mixture was incubated at 37°C for 1 h to allow the Exos membrane to recover, and then ultracentrifuged at 100,000 × g for 70 min in a low-temperature ultracentrifuge to collect the precipitate, namely salidroside-Exos.

[0023] The vesicle number is obtained by counting the vesicles in the exosome physiological saline suspension using nanoparticle tracking analysis (NTA) technology.

[0024] In the ultrasonic incubation method, the ultrasonic process is: power 20W, ultrasonic 5s, stop ultrasonic 5s, repeat this operation for 1min as a cycle, cycle 6 times, each cycle interval 2min. The ultrasonic incubation method allows salidroside to enter the exosomes, so that the exosomes are used as carriers to load salidroside. The ultrasonic conditions can achieve effective loading.

[0025] Therefore, the method for preparing exosomes loaded with salidroside provided by the present invention can load salidroside onto exosomes by using an ultrasonic incubation method.

[0026] The second aspect of the invention provides human umbilical cord mesenchymal stem cell exosomes loaded with salidroside obtained by the above-mentioned preparation method, which contains human umbilical cord mesenchymal stem cell exosomes and salidroside, the concentration of salidroside is 10-100 mg / mL, and the concentration of human umbilical cord mesenchymal stem cell exosomes is 1×10 10 -1×10 12 / mL, and the rest was normal saline.

[0027] At the above loading concentration, exosomes loaded with salidroside inhibited endometrial inflammation and fibrosis, improved pregnancy rate, and treated intrauterine adhesions, which were superior to salidroside treatment alone or exosome treatment alone.

[0028] Optionally, human umbilical cord mesenchymal stem cell exosomes loaded with salidroside contain human umbilical cord mesenchymal stem cell exosomes and salidroside, the concentration of salidroside is 10-100 mg / mL, and the concentration of human umbilical cord mesenchymal stem cell exosomes is 1×10 10 -1×10 12 / mL, and the rest is normal saline. The concentration of human umbilical cord mesenchymal stem cell exosomes is measured by the number of vesicles per unit volume. The concentration of salidroside is 10-100 mg / mL, which means that the concentration of salidroside in human umbilical cord mesenchymal stem cell exosomes loaded with salidroside can be 10 mg / mL, or 100 mg / mL, or any concentration between 10-100 mg / mL, such as 20 mg / mL, 30 mg / mL, 40 mg / mL, 50 mg / mL, 60 mg / mL, 70 mg / mL, 80 mg / mL, 90 mg / mL, etc.

[0029] A third aspect of the present invention provides use of exosomes loaded with salidroside in the preparation of a medicament for treating intrauterine adhesions.

[0030] When using exosomes loaded with salidroside, it can be used directly as a drug or as one of the active ingredients of the drug.

[0031] When applying the exosomes loaded with salidroside, the exosomes loaded with salidroside or the drug containing the exosomes loaded with salidroside can be injected into the endometrium.

[0032] Compared with the prior art, the present invention has at least the following beneficial effects:

[0033] Experiments have shown that exosomes loaded with salidroside for the preparation and treatment of intrauterine adhesions have advantages over salidroside alone or exosomes alone, so it can be used as a drug or one of the active ingredients of a drug to treat this disease. BRIEF DESCRIPTION OF THE DRAWINGS

[0034] Figure 1 This is the transmission electron microscopy imaging result of exosomes in Example 1.

[0035] Figure 2 is the average particle size of the exosome sample in Example 1.

[0036] Figure 3 This is the protein index result of the exosome sample in Example 1.

[0037] Figure 4 This is the expression diagram of fibrosis marker α-SMA. In the figure, A, B, C, D, E, and F are the groups after intervention on modeling rats, Group A: sham operation group, Group B: normal saline model group, Group C: estrogen group, Group D: salidroside-Exos group, Group E: hUC-MSCs exosome group, and Group F: salidroside group. DETAILED DESCRIPTION

[0038] In order to make the purpose, technical solution and advantages of the present invention more clearly understood, the present invention is further described in detail below in conjunction with the embodiments. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not used to limit the present invention.

[0039] Example 1 Isolation of exosomes from hUC-MSCs

[0040] Precool the cryogenic centrifuge and ultracentrifuge to 4°C, centrifuge the culture supernatant of human umbilical cord mesenchymal stem cells at 300g and 4°C for 10 minutes in a cryogenic centrifuge to remove cell debris; transfer the supernatant after centrifugation to an ultracentrifuge tube and make up with saline; centrifuge at 29500g and 4°C for 20 minutes in an ultracentrifuge to further remove cells and debris; filter with a 0.22μm pore size filter to remove particles larger than 200nm; transfer the filtered supernatant to another ultracentrifuge tube and centrifuge at 120000g and 4°C for 90 minutes in an ultracentrifuge. Discard the supernatant, absorb the liquid on the wall of the ultracentrifuge tube with sterile filter paper, and the bottom of the tube is exosomes (Exos), add saline to the ultracentrifuge tube, and store at -80°C for use.

[0041] Exosome identification process and results:

[0042] 1. Transmission electron microscopy observation of exosome samples

[0043] (1) Take out 10 μL of exosomes.

[0044] (2) Pipette 10 μL of the sample and drop it onto a copper grid to precipitate for 1 min. Use filter paper to remove the floating liquid.

[0045] (3) Add 10 μL of uranyl acetate onto the copper grid and allow to precipitate for 1 min. Remove the supernatant with filter paper.

[0046] (4) Dry at room temperature for several minutes.

[0047] (5) Transmission electron microscopy imaging was performed at 100 kV.

[0048] (6) The transmission electron microscopy imaging results show that the exosomes obtained are cup-shaped round or quasi-round membrane vesicles, which are consistent with the characteristics of exosomes. Figure 1 shown.

[0049] 2. Exosome sample particle size analysis

[0050] (1) Take the frozen samples, thaw them in a 25°C water bath, and place them on ice.

[0051] (2) The exosome samples were diluted with physiological saline and directly used for nanoparticle tracking analysis (NTA) detection. The results showed that the average particle size of the exosome (i.e., vesicle) samples was 125nm, which is consistent with the characteristics of exosomes (30nm-150nm). Figure 2 shown.

[0052] 3. Fluorescence labeling and nanoflow cytometry of exosome samples

[0053] (1) Take an appropriate amount of exosomes and dilute them to 90 μL with physiological saline. Take 30 μL of diluted exosomes and add 20 μL of fluorescently labeled antibodies (CD9, CD63, CD81) respectively, mix well, and incubate at 37°C for 30 min in the dark.

[0054] (2) Add 1 mL of physiological saline precooled to 4°C, select an ultracentrifuge rotor, and centrifuge at 4°C, 110,000 × g for 70 min.

[0055] (3) Carefully remove the supernatant, add 1 mL of physiological saline precooled to 4°C, select an ultracentrifuge rotor, and ultracentrifuge again at 4°C, 110,000 × g, for 70 min.

[0056] (4) Carefully remove the supernatant and resuspend the cell culture medium in 50 μL of pre-cooled saline.

[0057] (5) First, use standard samples to test the instrument performance of the nanoflow cytometer. Only after the test is qualified can the exosome sample be loaded. Note that the standard samples need to be diluted in a gradient manner to avoid clogging the injection needle with the sample.

[0058] (6) Once the sample is tested, the protein index results can be obtained. Figure 3 As shown, antibodies CD9\CD63\CD81 were all positive, indicating that the samples met the characteristics of exosomes.

[0059] Example 2 Exosomes carrying salidroside

[0060] Salidroside-Exos were prepared by ultrasonic incubation: Salidroside (10 mg) and exosomes (1×10 10 , calculated by the number of vesicles) was dissolved in physiological saline, and after ultrasonication in an ice bath (power 20W, ultrasonication for 5s, stop ultrasonication for 5s, repeat this operation for 1min as one cycle, cycle 6 times, cycle interval 2min), the mixture was incubated at 37°C for 1h to restore the Exos membrane, and then ultracentrifuged (100000×g, 70min) to collect salidroside-Exos. Salidroside-Exos was dissolved in physiological saline to 1mL.

[0061] Example 3 Exosomes carrying salidroside

[0062] Salidroside-Exos were prepared by ultrasonic incubation: Salidroside (50 mg) and exosomes (1×10 11 , calculated by the number of vesicles) was dissolved in physiological saline, and after ultrasonication in an ice bath (power 20W, ultrasonication for 5s, stop ultrasonication for 5s, repeat this operation for 1min as one cycle, cycle 6 times, cycle interval 2min), the mixture was incubated at 37°C for 1h to restore the Exos membrane, and then ultracentrifuged (100000×g, 70min) to collect salidroside-Exos. Salidroside-Exos was dissolved in physiological saline to 1mL.

[0063] Example 4 Exosomes carrying salidroside

[0064] Salidroside-Exos were prepared by ultrasonic incubation: Salidroside (100 mg) and exosomes (1×10 12 , calculated by the number of vesicles) was dissolved in physiological saline, and after ultrasonication in an ice bath (power 20W, ultrasonication for 5s, stop ultrasonication for 5s, repeat this operation for 1min as one cycle, cycle 6 times, cycle interval 2min), the mixture was incubated at 37°C for 1h to restore the Exos membrane, and then ultracentrifuged (100000g, 70min) to collect salidroside-Exos. Salidroside-Exos was dissolved in physiological saline to 1mL.

[0065] Study the repair effect and mechanism of salidroside-Exos on intrauterine adhesions in animal models:

[0066] 1. Establishment of intrauterine adhesion rat model, and intervention of model rats with salidroside-Exos prepared in Example 2:

[0067] (1) Sham operation group (Group A): rats were sutured layer by layer after laparotomy;

[0068] (2) Normal saline model group (Group B): After laparotomy, the lower 1 / 3 of the bilateral uterus was repeatedly scraped 20 times with a syringe, and then sutured layer by layer. The rats were allowed to wake up naturally. After 1 week, they were anesthetized again, and 10 μL of normal saline was injected into each bilateral uterine horn, followed by sutured layer by layer.

[0069] (3) Estrogen group (Group C): After laparotomy, rats underwent scraping surgery similar to that of the saline group. One week after surgery, they were anesthetized again and given oral estrogen treatment, and then the rats were allowed to wake up naturally.

[0070] (4) Salidroside-Exos group (Group D): After laparotomy, the rats underwent scraping surgery in the same manner as the saline group. One week after surgery, the rats were anesthetized again and injected with Salidroside-Exos into the bilateral uterine horns for treatment. The rats were then allowed to wake up naturally.

[0071] (5) hUC-MSCs exosome group (Group E): After laparotomy, rats underwent scraping surgery similar to the saline group. One week after surgery, they were anesthetized again and hUC-MSCs exosomes were injected into the bilateral uterine horns for treatment. The rats were then allowed to wake up naturally.

[0072] (6) Salidroside group (Group F): After laparotomy, the rats underwent scraping surgery similar to that of the saline group. One week after surgery, the rats were anesthetized again and salidroside was injected into the bilateral uterine horns for treatment. The rats were then allowed to wake up naturally.

[0073] 2. Data acquisition of experimental results: (1) Specimen collection: 7 days after treatment, the rats were anesthetized again, and bilateral uteri were removed by laparotomy; (2) HE staining was used to detect the thickness of the endometrium to obtain the data in Table 1. The specific steps of HE staining detection were as follows: rat uterine tissue was obtained, fixed and embedded in sections, dewaxed in xylene for 5 minutes, dehydrated with different concentrations of ethanol, stained with hematoxylin solution for 5 minutes, differentiated in differentiation solution for 30 seconds, soaked in tap water for 15 minutes, soaked in eosin for 1 minute, dehydrated with different concentrations of ethanol, transparentized with xylene, embedded in paraffin, and the morphology of the endometrium was observed under a microscope. Image analysis software was used to calculate the thickness of the endometrium and the number of glands; (3) Real-time fluorescence quantitative reverse transcription-polymerase chain reaction (real-time PCR, qRT-PCR) was used to detect the fibrosis marker α-smooth muscle actin (α-SMA) to obtain Figure 4 (4) Masson staining was used to detect the area of ​​endometrial stromal fibrosis to obtain the data in Table 1. The specific steps of Masson staining were as follows: the sections were routinely dewaxed, stained with Weigert iron hematoxylin stain, Ponceau acid fuchsin stain and aniline blue stain, respectively, dehydrated with different concentrations of ethanol, transparentized with xylene, fixed, observed under a microscope, and the endometrial fibrosis area ratio was calculated using image analysis software.

[0074] Table 1 Endometrial thickness, gland number and fibrosis area ratio in each group

[0075]

[0076] From Table 1 and Figure 4 It can be seen that compared with the estrogen group, salidroside group, and hUC-MSCs exosome group, the salidroside-Exos group increased the thickness of the endometrium and the number of glands. At the same time, the degree of endometrial fibrosis was inhibited by inhibiting the expression of the fibrosis marker α-SMA, making the average fibrosis area ratio lower than that of the normal saline model group, indicating that the function of the endometrium has been restored. Therefore, salidroside-Exos injected into the endometrium has the effect of treating intrauterine adhesions, and the therapeutic effect of salidroside-Exos is significantly better than that of salidroside alone, and is also significantly better than that of hUC-MSCs exosomes alone.

[0077] Although the present invention is described herein with reference to the illustrative embodiments of the present invention, it should be understood that those skilled in the art can design many other modifications and implementations, which will fall within the scope and spirit of the principles disclosed in the present application. More specifically, within the scope disclosed in the present application, multiple variations and improvements can be made to the components and / or layout of the subject combination layout. In addition to the variations and improvements made to the components and / or layout, other uses will also be apparent to those skilled in the art.

Claims

1. An exosome loaded with salidroside, It is characterized in that Contains human umbilical cord mesenchymal stem cell exosomes and salidroside.

2. The exosomes loaded with salidroside according to claim 1, It is characterized in that The concentration of salidroside was 10-100 mg / mL, and the concentration of human umbilical cord mesenchymal stem cell exosomes was 1×10 10 -1×10 12 / mL, the concentration of human umbilical cord mesenchymal stem cell exosomes is measured by the number of vesicles per unit volume, and the rest is normal saline.

3. The use of the exosomes loaded with salidroside according to claim 1, It is characterized in that Used for preparing medicine for treating intrauterine adhesions.

4. The use of the exosomes loaded with salidroside according to claim 3, It is characterized in that When using exosomes loaded with salidroside, it is directly used as a drug, or it is used as one of the active ingredients of the drug.

5. The use of the exosomes loaded with salidroside according to claim 4, It is characterized in that When applying the exosomes loaded with salidroside, the exosomes loaded with salidroside or the drug containing the exosomes loaded with salidroside are injected into the endometrium.

6. The method for preparing exosomes loaded with salidroside according to claim 1 or 2, It is characterized in that The preparation method comprises the following steps: (1) Isolation of exosomes from human umbilical cord mesenchymal stem cells; (2) Using human umbilical cord mesenchymal stem cell exosomes to carry salidroside: Exosomes loaded with salidroside were prepared by ultrasonic incubation.

7. The method for preparing exosomes loaded with salidroside according to claim 6, It is characterized in that The method of ultrasonic incubation is as follows: 10-100 mg of salidroside and 1×10 10 -1×10 12 The exosomes were dissolved in physiological saline, and after sonication in an ice bath, the mixture was incubated at 37°C for 1 h and then ultracentrifuged at 100,000 × g for 70 min in a low-temperature ultracentrifuge to collect the precipitate.

8. The method for preparing exosomes loaded with salidroside according to claim 7, It is characterized in that In the ultrasonic incubation method, the ultrasonic process is: power 20W, ultrasonic 5s, stop ultrasonic 5s, repeat this operation for 1min as a cycle, cycle 6 times, each cycle interval 2min.

9. The method for preparing exosomes loaded with salidroside according to claim 7 or 8, It is characterized in that The process of isolating human umbilical cord mesenchymal stem cell exosomes comprises: collecting human umbilical cord mesenchymal stem cell culture supernatant and separating exosomes by ultracentrifugation.

10. The method for preparing exosomes loaded with salidroside according to claim 9, It is characterized in that The following steps were used to isolate exosomes from human umbilical cord mesenchymal stem cells: (1) Precool a low-speed centrifuge and a low-speed ultracentrifuge to 4°C, and centrifuge the human umbilical cord mesenchymal stem cell culture supernatant at 300×g and 4°C for 10 min in a low-speed centrifuge; (2) Transfer the supernatant after centrifugation to an ultracentrifuge tube, make up with saline, and centrifuge in a low-temperature ultracentrifuge at 29,500 × g, 4°C for 20 min; (3) Filter the supernatant with a 0.22 μm pore size filter, transfer the supernatant to another ultracentrifuge tube, and centrifuge in a low-temperature ultracentrifuge at 120,000 × g, 4°C for 90 min; (4) Discard the supernatant and use sterile filter paper to absorb the liquid on the wall of the ultracentrifuge tube. The bottom of the ultracentrifuge tube is the exosomes. Add physiological saline to the exosomes and store at -80°C until use.

Citation Information

Patent Citations

  • Use of human pluripotent stem cell exosome loaded with resveratrol in preparation of drugs for treating reproductive system disease

    CN110123841A

  • Application of rhodiola rosea or salidroside in preparation of preparation for protecting and / or regulating cell exosome

    CN115645450A

  • Application of umbilical cord mesenchymal stem cell-derived exosome in preparation of medicine for preventing and / or treating uterine scar formation

    CN116687972A

Cited By

  • Application of enhanced mesenchymal stem cells and exosomes in chronic nephritis and renal failure

    CN120549978A